Peptide Comparison
FOXO4-DRIvsCartalax
A senolytic peptide that clears aged "zombie" cells to support healthy aging — run in short, cycled courses a few times a year.
Chondroprotective tripeptide bioregulator (Ala-Glu-Asp) that activates chondrogenic differentiation through SOX9/COL2A1/aggrecan upregulation, reverses senescence-associated secretory phenotype in aging chondrocytes, and provides geroprotective effects through SIRT-6 upregulation and p16/p21/p53 suppression
At a Glance
Quick
comparison
Dose Range
FOXO4-DRI
1–5 mg
Cartalax
2–5 mg
Frequency
FOXO4-DRI
Cycled — short courses 2–4 times per year, not daily year-round
Cartalax
Once daily
Administration
FOXO4-DRI
Subcutaneous injection
Cartalax
Oral (capsule)
Cycle Length
FOXO4-DRI
Short "hit-and-run" cycles: either 3 doses over about a week, or a 2-week 5-on/2-off course, repeated every 4–6 months
Cartalax
12+ weeks
Onset Speed
FOXO4-DRI
Works in bursts — senescent-cell clearance starts within days, and benefits build over the following weeks
Cartalax
Gradual (3-4 weeks)
Evidence Level
FOXO4-DRI
Preclinical only — animal and cell-culture studies; no human trials
Cartalax
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Senescent cell clearance
Tissue rejuvenation (animal)
Selectivity for old cells
Healthy-aging support
Anti-Aging
Healing & Recovery
Hormone Support
Technical Data
Compound
specifications
FOXO4-DRI
Molecular Formula
C228H388N86O64
Molecular Weight
5358 g/mol
Half-Life
Not formally established in humans; the D-retro-inverso design resists enzyme breakdown, giving longer stability than ordinary L-peptides
Bioavailability
Not established; animal studies used intraperitoneal injection. Oral bioavailability is not established
CAS Number
2460055-10-9
Cartalax
Molecular Formula
C12H19N3O8
Molecular Weight
333.3 g/mol
Half-Life
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids
Bioavailability
Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)
CAS Number
Not yet registered (research compound)
Protocols
Dosing
tiers
FOXO4-DRI
Cartalax
Applications
Best
suited for
FOXO4-DRI
Senescent ("zombie") cell research
FOXO4-DRI is one of the best-studied tools for selectively clearing senescent cells in the lab. In aged mice and in human cells grown in a dish, it removed these worn-out cells while leaving healthy ones largely alone [1][2].
Healthy-aging and tissue-function research
In its first study, aged mice regained fur density, kidney function, and physical fitness after treatment [1]. Later work showed renewed blood-vessel cell function and less artery stiffness in animals [3]. This makes it a key research compound for understanding how clearing old cells affects whole-body aging.
Mechanism and drug-design research
Because scientists have mapped exactly where it binds p53 [5], FOXO4-DRI is valuable for studying the FOXO4–p53 survival pathway and for designing future senolytic drugs.
Cartalax
Cartilage regeneration and protection in age-related osteoarthritis
Cartalax is particularly well-suited for individuals focused on cartilage regeneration and protection in age-related osteoarthritis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Connective tissue repair and maintenance in aging individuals
Cartalax is particularly well-suited for individuals focused on connective tissue repair and maintenance in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
Cartalax is particularly well-suited for individuals focused on geroprotective therapy targeting the sirt-6/senescence axis in musculoskeletal tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
Cartalax is particularly well-suited for individuals focused on complementing conventional osteoarthritis treatments with bioregulatory peptide therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
FOXO4-DRI
Common
- Temporary tiredness during a cycle
Uncommon
- Injection-site reactions
Serious
- Cancer-pathway caution and allergic reactions
Cartalax
Common
- Mild injection site reaction
- Mild GI discomfort
- Mild fatigue
- Transient joint stiffness
Uncommon
- Temporary increase in joint discomfort
Serious
- No documented serious adverse effects
Research Status
Safety
& evidence
FOXO4-DRI
Evidence Level
Preclinical only — animal and cell-culture studies; no human trials
FDA Status
Research compound (not approved for human use)
Safety Overview
FOXO4-DRI is generally run in short, spaced-out cycles, which keeps exposure low. The most common experiences are mild and short-lived: some tiredness or a flu-like feeling for a day or two during a cycle as your body clears dead cells, plus the usual minor injection-site soreness. The one real precaution worth taking seriously: because it activates p53, the protein that guards against cancer, anyone with active or recent cancer should only use it under an oncologist's care. If you are pregnant, breastfeeding, or under 18, skip it.
Contraindications
- xNo established human safety profile — any human use is experimental
- xActive or recent cancer (the p53 pathway it acts on is not characterized for this use in humans)
- xPregnancy and breastfeeding
- xChildren and adolescents
Cartalax
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive joint infection — treat infection before initiating peptide bioregulator therapy
- xMalignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated
Decision Guide
Which is
right for you?
Choose FOXO4-DRI if...
- Senescent cell clearance research
- Healthy-aging and longevity research
- Laboratory and preclinical study
Choose Cartalax if...
- Cartilage regeneration and protection in age-related osteoarthritis
- Connective tissue repair and maintenance in aging individuals
- Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
- Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy